When looking at the incidence of clinically significant prostate cancer, the incidence among MSH2 carriers was 3·6% (11 of 305; 95% CI 1·8 to 6·4) compared with 0% (none of 210) among MSH2 non-carrier controls (p=0·0037). The gene discussed is MSH2; the disease is prostate carcinoma.